Literature DB >> 22098309

Successful management of severe infant bullous pemphigoid with omalizumab.

C Dufour, A L Souillet, C Chaneliere, F Jouen, C Bodemer, D Jullien, F Cambazard, P Joly, P Reix.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22098309     DOI： 10.1111/j.1365-2133.2011.10748.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  20 in total

1.  Factors associated with the activity and severity of bullous pemphigoid: a review.

Authors:  Yangchun Liu; Yiman Wang; Xinyi Chen; Hongzhong Jin; Li Li
Journal:  Ann Med       Date:  2020-03-22       Impact factor: 4.709

Review 2.  Off-Label Uses of Omalizumab.

Authors:  David El-Qutob
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

Review 3.  Unraveling the significance of IgE autoantibodies in organ-specific autoimmunity: lessons learned from bullous pemphigoid.

Authors:  K A N Messingham; H M Holahan; J A Fairley
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

4.  [Bullous pemphigoid: a new look at a well-known disease].

Authors:  G Balakirski; H F Merk; M Megahed
Journal:  Hautarzt       Date:  2014-12       Impact factor: 0.751

5.  T cell participation in autoreactivity to NC16a epitopes in bullous pemphigoid.

Authors:  W J Pickford; V Gudi; A M Haggart; B J Lewis; R Herriot; R N Barker; A D Ormerod
Journal:  Clin Exp Immunol       Date:  2015-05       Impact factor: 4.330

6.  Human eosinophils express the high affinity IgE receptor, FcεRI, in bullous pemphigoid.

Authors:  Kelly N Messingham; Heather M Holahan; Alexandra S Frydman; Colleen Fullenkamp; Rupasree Srikantha; Janet A Fairley
Journal:  PLoS One       Date:  2014-09-25       Impact factor: 3.240

Review 7.  IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.

Authors:  Arnau Navinés-Ferrer; Eva Serrano-Candelas; Gustavo-J Molina-Molina; Margarita Martín
Journal:  J Immunol Res       Date:  2016-12-21       Impact factor: 4.818

8.  Successful Treatment of a Bullous Pemphigoid Patient with Rituximab Who Was Refractory to Corticosteroid and Omalizumab Treatments.

Authors:  Aslı Bilgiç Temel; Cumhur Ibrahim Bassorgun; Ayşe Akman-Karakaş; Erkan Alpsoy; Soner Uzun
Journal:  Case Rep Dermatol       Date:  2017-02-10

9.  Bullous pemphigoid in infants: characteristics, diagnosis and treatment.

Authors:  Agnes Schwieger-Briel; Cornelia Moellmann; Birgit Mattulat; Franziska Schauer; Dimitra Kiritsi; Enno Schmidt; Cassian Sitaru; Hagen Ott; Johannes S Kern
Journal:  Orphanet J Rare Dis       Date:  2014-12-10       Impact factor: 4.123

Review 10.  IgE autoantibodies and their association with the disease activity and phenotype in bullous pemphigoid: a systematic review.

Authors:  Ariadne Hadjikyriacou Saniklidou; Patrick J Tighe; Lucy C Fairclough; Ian Todd
Journal:  Arch Dermatol Res       Date:  2017-10-25       Impact factor: 3.017
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.